Adela Presents Data Demonstrating Ability of Tissue-Free MRD Test to Predict Recurrence in Lung Cancer at the American Association for Cancer Research Annual Meeting 2025

Adela Presents Data Demonstrating Ability of Tissue-Free MRD Test to Predict Recurrence in Lung Cancer at the American Association for Cancer Research Annual Meeting 2025

FOSTER CITY, Calif., April 28, 2025 /PRNewswire/ -- Adela, Inc., an innovator in blood testing for molecular residual disease (MRD) monitoring and early cancer detection through a proprietary genome-wide methylome enrichment technology, presented initial results demonstrating the ability of its…